TAK-438

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: TAK-438
• 英文别名: Vonoprazan (Fumarate)；but-2-enedioic acid;1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamine
• 化学式: C₄H₄O₄*C₁₇H₁₆FN₃O₂S
• 分子量: 461.471
• InChiKey: ROGSHYHKHPCCJW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.36
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  147
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  2-(2-氟苯基)-4-甲基-1H-吡咯 在 N-溴代丁二酰亚胺(NBS) 、 三乙胺 、 3-butyl-1-methyl-1H-imidazol-3-ium hexafluorophosphate 、 过氧化苯甲酰 作用下， 以 四氯化碳 、 二氯甲烷 、 甲苯 为溶剂， 反应 11.0h， 生成 TAK-438
  参考文献：
  名称：

  富马酸沃诺拉赞的制备工艺

  摘要：

  本发明涉及一种富马酸沃诺拉赞的制备工艺，是以邻氟苯乙酮(Ⅱ)与醋酸铵反应生成邻氟苯乙烯胺(Ⅲ)，再与2‑溴丙醛进行环合生成5‑(2‑氟苯基)‑3‑甲基‑1H‑吡咯(Ⅳ)，该化合物Ⅳ与3‑吡啶磺酰氯反应生成5‑(2‑氟苯基)‑3‑甲基‑1‑(吡啶‑3‑基磺酰基)‑1H‑吡咯(Ⅴ)，再通过N‑溴代琥珀酰亚胺取代生成5‑(2‑氟苯基)‑3‑溴代甲基‑1‑(吡啶‑3‑基磺酰基)‑1H‑吡咯(Ⅵ)，最后经过甲胺化反应，成盐得到富马酸沃诺拉赞。该方法避免了现有技术中有毒试剂液溴及对设备有腐蚀氯化氢气体的使用，具有工艺路线简单、反应条件温和、操作可控，对环境友好、产品收率高的优点，适宜大规模工艺化生产。

  公开号：

  CN105294653B

文献信息

• Acid secretion inhibitor
  申请人：Kajino Masahiro

  公开号：US20070060623A1

  公开（公告）日：2007-03-15

  The present invention provides a compound having a superior acid secretion inhibitory effect and showing an antiulcer activity and the like. The present invention provides a compound represented by the formula (I) wherein R 1 is a nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle, the nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle optionally has substituent(s), R 2 is an optionally substituted C 6-14 aryl group, an optionally substituted thienyl group or an optionally substituted pyridyl group, R 3 and R 4 are each a hydrogen atom, or one of R 3 and R 4 is a hydrogen atom and the other is an optionally substituted lower alkyl group, an acyl group, a halogen atom, a cyano group or a nitro group, and R 5 is an alkyl group or a salt thereof.

  本发明提供一种具有优越的抑制酸分泌作用并显示抗溃疡活性等的化合物。本发明提供一种由式(I)表示的化合物，其中R1是一种含氮的单环杂环基，可选择地与苯环或杂环缩合，该含氮的单环杂环基可选择地与苯环或杂环缩合，可选择地具有取代基，R2是可选择地取代的C6-14芳基，可选择地取代的噻吩基或可选择地取代的吡啶基，R3和R4分别是氢原子，或者R3和R4中的一个是氢原子，另一个是可选择地取代的较低烷基基团、酰基、卤原子、氰基或硝基，R5是烷基或其盐。
• [EN] METHODS OF MODULATING CFTR ACTIVITY<br/>[FR] PROCÉDÉS DE MODULATION DE L'ACTIVITÉ DE CFTR
  申请人：PROTEOSTASIS THERAPEUTICS INC

  公开号：WO2014210159A1

  公开（公告）日：2014-12-31

  The invention encompasses methods of modulating CFTR activity in a subject in need thereof comprising administering an effective amount of a compound of Formula (I). The invention also encompasses methods of treating a condition associated with CFTR activity or condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a compound of Formula (I).

  这项发明涵盖了在需要的受试者中调节CFTR活性的方法，包括向受试者施用化合物Formula (I)的有效量。该发明还涵盖了治疗与CFTR活性相关的疾病或与蛋白质稳态功能障碍相关的疾病的方法，包括向受试者施用化合物Formula (I)的有效量。
• PROCESS FOR PRODUCING PYRROLE COMPOUND
  申请人：Ikemoto Tomomi

  公开号：US20110306769A1

  公开（公告）日：2011-12-15

  The present invention provides a production method of a sulfonylpyrrole compound useful as a pharmaceutical product, a production method of an intermediate used for the method, and a novel intermediate. The present invention relates to a method of producing sulfonylpyrrole compound (VIII), which includes reducing compound (III) and hydrolyzing the reduced product to give compound (IV), subjecting compound (IV) to a sulfonylation reaction to give compound (VI), and subjecting compound (VI) to an amination reaction.

  本发明提供了一种作为药物产品有用的磺酰吡咯化合物的生产方法，一种用于该方法的中间体的生产方法，以及一种新的中间体。本发明涉及一种生产磺酰吡咯化合物（VIII）的方法，包括还原化合物（III）并水解还原产物以得到化合物（IV），将化合物（IV）经过磺酰化反应得到化合物（VI），并将化合物（VI）经过胺化反应。
• 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITOR
  申请人：Kajino Masahiro

  公开号：US20090275591A1

  公开（公告）日：2009-11-05

  The present invention provides a compound having a superior acid secretion inhibitory effect and showing an antiulcer activity and the like. The present invention provides a compound represented by the formula (I) wherein R 1 is a nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle, the nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle optionally has substituent(s), R 2 is an optionally substituted C 6-14 aryl group, an optionally substituted thienyl group or an optionally substituted pyridyl group, R 3 and R 4 are each a hydrogen atom, or one of R 3 and R 4 is a hydrogen atom and the other is an optionally substituted lower alkyl group, an acyl group, a halogen atom, a cyano group or a nitro group, and R 5 is an alkyl group or a salt thereof.

  本发明提供一种具有优异的抑制酸分泌作用并具有抗溃疡活性等的化合物。本发明提供一种由式（I）表示的化合物，其中R1是一种含氮的单环杂环基，可选择与苯环或杂环缩合，该含氮的单环杂环基可选择与苯环或杂环具有取代基，R2是可选择取代的C6-14芳基、可选择取代的噻吩基或可选择取代的吡啶基，R3和R4分别是氢原子，或者R3和R4中的一个是氢原子，另一个是可选择取代的低碳基、酰基、卤素原子、氰基或硝基，R5是烷基或其盐。
• Proton Pump Inhibitors
  申请人：Kajino Masahiro

  公开号：US20080139639A1

  公开（公告）日：2008-06-12

  A proton pump inhibitor containing a compound represented by the formula (I) wherein X and Y are the same or different and each is a bond or a spacer having 1 to 20 carbon atoms in the main chain, R 1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R 2 , R 3 and R 4 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted thienyl group, an optionally substituted benzo[b]thienyl group, an optionally substituted furyl group, an optionally substituted pyridyl group, an optionally substituted pyrazolyl group, an optionally substituted pyrimidinyl group, an acyl group, a halogen atom, a cyano group or a nitro group, R 5 and R 6 are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, which has a superior proton pump action and shows an antiulcer activity and the like after conversion to a proton pump inhibitor in the body, or a salt thereof. or a prodrug thereof is provided.

  提供一种质子泵抑制剂，其中包含公式（I）所代表的化合物，其中X和Y相同或不同，每个都是具有1到20个碳原子的主链中的键或间隔物，R1是可选取代的碳氢化合物基团或可选取代的杂环基团，R2、R3和R4相同或不同，每个都是氢原子、可选取代的碳氢化合物基团、可选取代的噻吩基团、可选取代的苯并[b]噻吩基团、可选取代的呋喃基团、可选取代的吡啶基团、可选取代的吡唑基团、可选取代的嘧啶基团、酰基、卤素原子、氰基或硝基，R5和R6相同或不同，每个都是氢原子或可选取代的碳氢化合物基团。该化合物在体内转化为质子泵抑制剂后具有卓越的质子泵作用，并显示抗溃疡活性等，或其盐或前药。